Research location
Obninsk
Russia
Advertisement
Research activity in Obninsk
RussiaCureCurrent currently publishes aggregate city-level research activity for this location: 75 trials and 77 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Obninsk
75 linked trials · page 1 of 2Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDerationNCT07052578 · 2025-06-30 · 1 site observation
RECRUITING
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast CancerNCT07108309 · 2024-07-15 · 2 site observations
RECRUITING
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian FederationNCT07146113 · 2025-06-30 · 1 site observation
SUSPENDED
A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian FederationNCT06625333 · 2024-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)NCT06606847 · 2024-09-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerNCT07386938 · 2024-08-09 · 2 site observations
ACTIVE_NOT_RECRUITING
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic AlterationsNCT06245837 · 2024-03-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaNCT05751928 · 2023-04-05 · 1 site observation
ACTIVE_NOT_RECRUITING
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in RussiaNCT05887011 · 2023-03-31 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaNCT05732805 · 2022-08-02 · 1 site observation
ACTIVE_NOT_RECRUITING
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT03850795 · 2021-03-15 · 1 site observation
TERMINATED
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerNCT04351555 · 2020-12-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation
COMPLETED
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate CancerNCT04028388 · 2019-07-17 · 1 site observation
COMPLETED
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerNCT03800134 · 2018-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsNCT03706690 · 2018-11-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast CancerNCT03433313 · 2018-10-16 · 1 site observation
COMPLETED
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNCT03539536 · 2018-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT03703297 · 2018-09-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)NCT03521154 · 2018-07-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ANCT03447769 · 2018-03-16 · 1 site observation
TERMINATED
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPCNCT02489318 · 2015-11-27 · 1 site observation
ACTIVE_NOT_RECRUITING
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASNCT02531516 · 2015-11-19 · 1 site observation
ACTIVE_NOT_RECRUITING
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.NCT02511106 · 2015-10-21 · 1 site observation
ACTIVE_NOT_RECRUITING
An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).NCT02321046 · 2015-09-02 · 1 site observation
COMPLETED
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)NCT02453282 · 2015-07-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast CancerNCT02294786 · 2014-12-17 · 1 site observation
TERMINATED
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerNCT02200614 · 2014-09-12 · 1 site observation
COMPLETED
OVArian Cancer Non-Interventional Study - OVATARNCT02122588 · 2014-06-30 · 1 site observation
COMPLETED
Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate CancerNCT03074032 · 2014-06-30 · 1 site observation
COMPLETED
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast CancerNCT02162667 · 2014-06-01 · 1 site observation
COMPLETED
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerNCT02032277 · 2014-04-02 · 1 site observation
COMPLETED
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild SymptomsNCT02043678 · 2014-03-30 · 1 site observation
COMPLETED
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung CancerNCT01999673 · 2013-12-01 · 1 site observation
COMPLETED
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerNCT01946204 · 2013-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Long-term Extension Study of PCI-32765 (Ibrutinib)NCT01804686 · 2013-09-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical CareNCT02236637 · 2013-06-14 · 1 site observation
COMPLETED
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)NCT01715285 · 2013-02-12 · 1 site observation
COMPLETED
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.NCT01753297 · 2012-12-11 · 1 site observation
COMPLETED
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerNCT01630733 · 2012-10-24 · 1 site observation
COMPLETED
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to HistopathologyNCT01667536 · 2012-08-01 · 1 site observation
COMPLETED
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone MetastasesNCT01618370 · 2012-07-22 · 1 site observation
COMPLETED
Phase III Study Comparing the Efficacy and Safety of EP2006 and FilgrastimNCT01519700 · 2011-12-01 · 1 site observation
COMPLETED
Open-Label Access Protocol of Denosumab for Subjects With Advanced CancerNCT01419717 · 2011-11-22 · 1 site observation
COMPLETED
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate CancerNCT01308580 · 2011-04-01 · 1 site observation
COMPLETED
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)NCT01234025 · 2010-11-01 · 1 site observation
COMPLETED
LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or GefitinibNCT01085136 · 2010-02-01 · 1 site observation
COMPLETED
Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN)NCT01069835 · 2010-02-01 · 1 site observation
COMPLETED
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate CancerNCT00988208 · 2009-11-11 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.